Loading...
•
Dec 31, 2025
Standard Biotool Q4 2025 Earnings Report
Standard BioTools reported its fourth quarter and full year 2025 financial results, highlighting significant cost savings and a path toward 2026 profitability.
Key Takeaways
Standard BioTools delivered Q4 revenue of $23.8 million, down 4% year-over-year, but showed improved operational efficiency. The company successfully operationalized over $40 million in annualized cost savings and significantly improved its net income position due to a one-time tax benefit, while maintaining a strong cash position of approximately $550 million following the SomaLogic transaction.
Operationalized over $40 million in annualized cost savings to support the path to positive adjusted EBITDA by 2026.
Q4 Net Income turned positive at $13.9 million, primarily driven by a $38.4 million non-cash partial release of a tax valuation allowance.
Instruments revenue grew 10% year-over-year in Q4, driven by strong performance in imaging.
Maintained a robust balance sheet with approximately $550 million in cash and investments post-SomaLogic transaction closing in January 2026.
Revenue by Segment
Forward Guidance
For fiscal year 2026, Standard BioTools expects revenue to be between $80 million and $85 million.
Positive Outlook
- Path to positive adjusted EBITDA exiting 2026.
- Strong balance sheet with ~$550M in cash to fuel inorganic growth.
- Approximately $1 billion in NOL carryforwards available.
- Full operationalization of $40M+ in cost savings.
- Strong growth in imaging instrument sector.
Challenges Ahead
- Full year 2026 revenue guidance ($80M-$85M) is flat to down vs 2025 ($85.3M).
- Capital-constrained end-markets impacting instrument sales.
- Declining consumables revenue due to project funding shifts.
- Lower on-demand service revenue due to improved instrument uptime.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...